ERBB2 and neoplasm: The HER2 antibody component of T-DXd consists of a human monoclonal immunoglobulin G1 produced with reference to the same amino acid sequence as trastuzumab.6 The molecule includes a topoisomerase I inhibitor payload, DXd, that is attached to the antibody by a tumor-selective cleavable linker.